Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 31, Issue 5, 2013, Pages 691-698

  Crilly, Michael A ^a   Mangoni, Arduino A ^a   Knights, Kathleen M ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Aldosterone; Arterial dysfunction; Non steroidal anti inflammatory drugs; Pulse wave analysis; Rheumatoid arthritis

Indexed keywords

ALDOSTERONE; AZATHIOPRINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE GLUCURONIDATION INHIBITION; ANALYTICAL EQUIPMENT; ARTERIAL WAVE REFLECTION; ARTERY DISEASE; ARTHRITIS; ARTICLE; AUGMENTATION INDEX; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLUCURONIDATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION CONSTANT; KIDNEY CORTEX; KIDNEY MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MEDICAL RECORD REVIEW; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PULSE WAVE; QUESTIONNAIRE; REFLECTED WAVE TRANSIT TIME; RHEUMATOID ARTHRITIS;

ADULT; AGED; ALDOSTERONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; FEMALE; GLUCURONIDES; HUMANS; KIDNEY CORTEX; LINEAR MODELS; MALE; MICROSOMES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULSE WAVE ANALYSIS; PYRAZOLES; RISK FACTORS; SULFONAMIDES; VASCULAR DISEASES; VASCULAR STIFFNESS;

EID: 84884998227     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. KEARNEY PM, BAIGENT C, GODWIN J, HALLS H, EMBERSON JR, PATRONO C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332; 1302-8.
2. McGETTIGAN P, HENRY D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633- 44.
3. KNIGHTS KM, MANGONI AA, MINERS JO: Non-selective non-steroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?. Br J Clin Pharmacol 2006; 61: 738-40.
4. KNIGHTS KM, MANGONI AA, MINERS JO: Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol 2010; 3: 769-76.
5. MANGONI AA, CRILLY MA, KNIGHTS KM: Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity. Expert Rev Clin Pharmacol 2011; 4: 299-302.
6. WARNER TD, MITCHELL JA: COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal antiinflammatory drugs. Lancet 2008; 19: 371; 270-3.
7. KIRKBY NS, LUNDBERG MH, HARRINGTON LS et al.: Cyclooxygenase-1, not cyclooxygenase- 2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA 2012; 109: 17597-602.
8. AVINA-ZUBIETA JA, CHOI HK, SADATSAFAVI M, ETMINAN M, ESDAILE JM, LACAILLE D: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
9. AVALOS I, CHUNG CP, OESER A et al.: Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J Rheumatol 2007; 34: 2388-94.
10. KLOCKE R, COCKCROFT JR, TAYLOR GJ, HALL IR, BLAKE DR: Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003; 62; 414-8.
11. van DOORNUM S., McCOLL G, WICKS IP: Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63; 1571-5.
12. MacKENZIE IS, WILKINSON IB, COCKCROFT JR: Assessment of arterial stiffness in clinical practice. QJM 2002; 95; 67-74.
13. SMULYAN H, SIDDIQUI DS, CARLSON RJ, LONDON GM, SAFAR ME: Clinical utility of aortic pulses and pressures calculated from applanated radial-artery pulses. Hypertension 2003; 42; 150-5.
14. PIERINGER H, SCHUMACHER S, STUBY U, BIESENBACH G: Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum 2009; 39: 163-9
15. VLACHOPOULOS C, AZNAOURIDIS K, O'ROURKE MF, SAFAR ME, BAOU K, STEFANADIS C: Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and metaanalysis. Eur Heart J 2010; 31; 1865-71.
16. KNIGHTS KM, WINNER LK, ELLIOT DJ, BOWALGAHA K, MINERS JO: Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009; 68; 402-12.
17. MAHMUD A, FEELY J: Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5; 102-8.
18. STRUTHERS AD: Aldosterone blockade in cardiovascular disease. Heart 2004; 90; 1229-34.
19. TOMASCHITZ A, PILZ S, RITZ E, MEINITZER A, BOEHM BO, MARZ W: Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010; 31; 1237-47.
20. BERNINI G, GALETTA F, FRANZONI F et al.: Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008; 26; 2399-405.
21. CRILLY MA, MANGONI AA: Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study. BMJ Open 2011; 1: e000076.
22. CRILLY MA, KUMAR V, CLARK HJ, SCOTT NW, MacDONALD AG, WILLIAMS DJ: Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors. Rheumatology (Oxford) 2009; 48; 1606-12.
23. CRILLY MA, CLARK HJ, KUMAR V, SCOTT NW, MacDONALD AG, WILLIAMS DJ: Relationship between arterial stiffness and Stanford Health Assessment Questionnaire disability in rheumatoid arthritis patients without overt arterial disease. J Rheumatol 2010; 37; 946-52.
24. BRUCE B, FRIES JF: The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003; 1: 20.
25. RABIN R, DE CHARRO F: EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001; 33; 337-43.
26. van BORTEL LM, DUPREZ D, STARMANSKOOL MJ et al.: Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens 2002; 15; 445-52.
27. EL ASSAAD MA, TOPOUCHIAN JA, ASMAR RG: Evaluation of two devices for selfmeasurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit 2003; 8; 127-33.
28. CRILLY M, COCH C, BRUCE M, CLARK H, WILLIAMS D: Indices of cardiovascular function derived from peripheral pulse wave analysis using radial applanation tonometry: a measurement repeatability study. Vasc Med 2007; 12; 189-97.
29. PAUCA AL, O'ROURKE MF, KON ND: Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38; 932-7.
30. WILKINSON IB, MacCALLUM H, FLINT L, COCKCROFT JR, NEWBY DE, WEBB DJ: The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525; 263-70.
31. MATTHEWS JN, ALTMAN DG, CAMPBELL MJ, ROYSTON P: Analysis of serial measurements in medical research. BMJ 1990; 300; 230-5.
32. ROWLAND A, GAGANIS P, ELLIOT DJ, Mac- KENZIE PI, KNIGHTS KM, MINERS JO: Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 2007; 321; 137-47.
33. DAVIES NM, McLACHLAN AJ, DAY RO, WILLIAMS KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38; 225-42.
34. WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96; 7563-8.
35. CLARIDGE M, HOBBS S, QUICK C, DAY N, BRADBURY A, WILMINK T: Nonsteroidal antiinflammatory drugs are associated with increased aortic stiffness. Vasc Health Risk Manag 2005; 1; 149-53.
36. WONG M, JIANG BY, McNEILL K, FARISH S, KIRKHAM B, CHOWIENCZYK P: Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36; 265-9.
37. PANOULAS VF, DOUGLAS KM, MILIONIS HJ et al.: Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46; 1477-82.
38. CHAN CC, REID CM, AW TJ, LIEW D, HAAS SJ, KRUM H: Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27; 2332-41.